Table 1.
Clinical and pathologic parameters of 20 patients undergoing cytoreductive radical prostatectomy and extended pelvic lymph node dissection for oligometastatic prostate cancer after systemic therapy
| Baseline parameters at diagnosis and initial staging using [68Ga]Ga-PSMA-11 PET | |
|---|---|
| Age (yr), median (IQR) | 64.5 (60–68) |
| PSA (ng/ml), median (IQR) | 37 (13.7–91) |
| ISUP, n (%) | |
| 3 | 1 (5.0) |
| 4 | 11 (55.0) |
| 5 | 8 (40.0) |
| cT, n (%) | |
| 2 | 1 (5.0) |
| 3a | 5 (25.0) |
| 3b | 10 (50.0) |
| 4 | 4 (20.0) |
| cN, n (%) | |
| 0 | 1 (5.0) |
| 1 | 19 (95.0) |
| cM, n (%) | |
| 0 | 12 (60.0) |
| 1a | 2 (10.0) |
| 1b | 3 (15.0) |
| 1 | 3 (15.0) |
| Baseline NM staging using conventional imaging | |
| cN, n (%) | |
| 0 | 3 (15.0) |
| 1 | 17 (85.0) |
| cM, n (%) | |
| 0 | 16 (80.0) |
| 1a | 1 (5.0) |
| 1b | 2 (10.0) |
| 1 | 1 (5.0) |
| Preoperative parameters and staging using [68Ga]Ga-PSMA-11 PET | |
| Age (yr), median (IQR) | 65.5 (61–69) |
| PSA (ng/ml), median (IQR) | 0.39 (0.04–0.67) |
| ADT duration (mo), median (IQR) | 8.5 (6–12.5) |
| Docetaxel, n (%) | |
| Yes | 11 (55.0) |
| No | 9 (45.0) |
| Enzalutamide, n (%) | |
| Yes | 6 (30.0) |
| No | 14 (70.0) |
| ycT, n (%) | |
| 0 | 3 (15.0) |
| 2 | 11 (55.0) |
| 3a | 1 (5.0) |
| 3 | 5 (25.0) |
| ycN, n (%) | |
| 0 | 13 (65.0) |
| 1 | 8 (35.0) |
| ycM, n (%) | |
| 0 | 16 (80.0) |
| 1a | 2 (10.0) |
| 1b | 2 (10.0) |
| Pathologic results at surgery | |
| ypT, n (%) | |
| 0 | 3 (15.0) |
| 2 | 4 (20.0) |
| 3a | 5 (25.0) |
| 3b | 8 (40.0) |
| ypN, n (%) | |
| 0 | 10 (50.0) |
| 1 | 10 (50.0) |
| PSM, n (%) | |
| 0 | 11 (55.0) |
| 1 | 9 (45.0) |
| LVI, n (%) | |
| 0 | 13 (65.0) |
| 1 | 7 (35.0) |
| PNI, n (%) | |
| 0 | 5 (25.0) |
| 1 | 15 (75.0) |
| LN removed, median (IQR) | 37 (21.5–46) |
| LN positive, median (IQR) | 1 (0–5) |
| Postoperative PSA (ng/ml), median (IQR)a | 0.03 (0.01–0.08) |
ADT = androgen deprivation therapy; IQR = interquartile range; ISUP = International Society of Urological Pathology Gleason grade group; LN = lymph node; LVI = lymphovascular invasion; PET = positron emission tomography; PNI = perineural invasion; PSA = prostate-specific antigen; PSM = positive surgical margin; PSMA = prostate-specific membrane antigen.
a
Measured 6 wk postoperatively.